Genetically modified non-human animals and methods of use thereof
Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.
1. A method of producing an antigen-binding protein, the method comprising:
immunizing an engrafted, genetically modified, Rag-2 −/− IL-2rg null mouse with an antigen, wherein the mouse comprises
a genome comprising a nucleic acid encoding human IL-6, wherein the nucleic acid encoding human IL-6 replaces the endogenous mouse IL-6 gene at the endogenous mouse IL-6 gene locus, and wherein the nucleic acid encoding human IL-6 is operably linked to the endogenous mouse IL-6 promoter, and
an engraftment of human hematopoietic cells,
wherein, following the immunizing, the mouse produces a human B cell comprising an antigen-binding protein that specifically binds the antigen.
2. The method of claim 1 , further comprising collecting from said mouse at least one of the spleen, the lymph nodes, the peripheral blood, the bone marrow, or portions thereof of the mouse.
3. The method of claim 2 , further comprising isolating the human B cell from at least one of the spleen, the lymph nodes, the peripheral blood, the bone marrow, or portions thereof of the mouse.
4. The method of claim 3 , further comprising isolating the antigen-binding protein from the human B cell.
5. The method of claim 3 , further comprising producing a hybridoma cell line from the human B cell.
6. The method of claim 5 , further comprising isolating from the hybridoma cell line an antigen-binding protein that specifically binds the antigen.
7. The method of claim 1 , wherein the antigen-binding protein is a human IgG.
8. The method of claim 1 , wherein the human hematopoietic cells comprise CD34+ cells.
9. The method of claim 1 , wherein the human hematopoietic cells are obtained from one or more of human fetal liver, human bone marrow, human cord blood, human peripheral blood, and human spleen.
10. The method of claim 1 , wherein the antigen is at least one of a peptide, a MHC/peptide complex, a DNA, a live virus, a dead virus or portion thereof, a live bacteria, a dead bacteria or portion thereof, and a cancer cell or portion thereof.
11. The method of claim 1 , wherein the antigen is administered to the engrafted, genetically modified, immunodeficient mouse about 1-5 months after engraftment of the human hematopoietic cells.
12. The method of claim 1 , wherein the engrafted, genetically modified mouse does not express mouse IL-6.
13. The method of claim 1 , wherein the engrafted, genetically modified mouse comprises a genome further comprising a nucleic acid encoding human SIRPa, wherein the nucleic acid is operably linked to a promoter.
14. A method of isolating an antigen-binding protein, the method comprising:
isolating from an engrafted, genetically modified, Rag-2 −/− IL-2rg null mouse a human B cell producing an antigen-binding protein that specifically binds an antigen,
wherein the mouse comprises
a genome comprising a nucleic acid encoding human IL-6, wherein the nucleic acid encoding human IL-6 replaces the endogenous mouse IL-6 gene at the endogenous mouse IL-6 gene locus, and wherein the nucleic acid encoding human IL-6 is operably linked to the endogenous mouse IL-6 promoter, and
an engraftment of human hematopoietic cells, and
wherein the mouse has been immunized with the antigen.